| abstract |
The present invention discloses a type of multi-branched drug conjugate that can specifically target CD44. Such compounds specifically bind to CD44 and can target tumor cells and tissues that highly express CD44, so that the concentration of the conjugate in target tissues is higher, which improves its clinical therapeutic effect and reduces toxicity. The compounds of the present invention are suitable for the treatment of all tumors with high CD44 expression, including but not limited to gastric cancer, pancreatic cancer, small cell lung cancer, colon cancer, breast cancer, lung adenocarcinoma, liver cancer, nasopharyngeal carcinoma, malignant glioma, lymphoma, kidney Cancer, ovarian cancer, head and neck cancer, squamous cell carcinoma, etc. |